In January, WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable lenacapavir as pre-exposure prophylaxis (PrEP) for HIV, and the optimization of HIV testing services for long-acting prevention products. These updates reflect WHO’s commitment to addressing evolving public health needs, particularly for populations disproportionately affected by HIV, and to improving access to high-quality HIV prevention and testing services globally.

GDG members will contribute to the review of systematic reviews, evidence summaries, technical updates, and will propose recommendations. They will also participate in the GDG meeting, which will be held virtually between 28 and 30 January 2025.

The general objective of this meeting is to develop WHO guidelines that will serve as a normative framework for the implementation of lenacapavir, a new HIV prevention product, and for simplified testing delivery models for pre-existing and new long-acting HIV prevention products.

Guideline Development Group composition

In accordance with WHO guidelines for developing recommendations, the GDG is composed of members from all WHO regions, serving in their individual capacities rather than as representatives of affiliated organizations. Members do not receive financial compensation for their contributions to this process.